Which non-steroidal anti-inflammatory drug should be used in patients with increased risk of gastrointestinal toxicity?
Commentary on CONDOR study

Czech version

Authors: M. Bortlík ^1,2; M. Lukáš ^1,3
Authors‘ workplace: Klinické a výzkumné centrum pro střevní záněty, ISCARE a 1. LF UK v Praze ¹; Interní klinika, 1. LF UK a ÚVN Praha ²; Ústav klinické biochemie a laboratorní diagnostiky, 1. LF UK v Praze ³
Published in: Gastroent Hepatol 2011; 65(3): 159-160
Category: Commentary

Sources

1. Lukáš M, Chalupná P, Adamec S et al. Adverse effects of non-steroidal antirheumatic agents on the digestive tract. Sb Lek 2002; 103(2): 265–272.

2. Ng SC, Chan FLK. NSAID-induced gastrointestinal and cardiovascular injury. Curr Opin Gastroenterol 2010; 26(6): 611–617.

3. Chan FKL, Lanas A, Scheiman J et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376(9736): 173–179.

4. Spiegel BMR, Farid M, Dulai GS et al. Comparing rates of dyspepsia with coxibs vs NSAID+PPI: a meta-analysis. Am J Med 2006; 119(5): 448.